Thus, this research underscores the potential of NPs-based technology in improving HCC treatment outcomes with special emphasis on the role of CD133-antibody conjugated PLGA NPs to selectively target and deliver Q or K to CSCs in the Huh7 cell line. This evidence concerns the gene PROM1 and hepatocellular carcinoma.